Estructura y mecanismo de accin Tanto LIRA como SEMA son AgGLP-1 de administracin subcutnea que mantienen una homologa del 97% y del 94%, respectivamente, en relacin con la molcula nativa de GLP-1
These findings, along with indications of safety and potential benefits for PAD outcomes, suggest that GLP-1RAs could be considered a preferred therapy over other anti-diabetic medications for patients with concurrent T2DM and PAD [79]
[DOI] [PubMed] [Google Scholar] 43.Holmes S., Male A.J., Ramdharry G., Woodward C., James N., Skorupinska I., Skorupinska M., Germain L., Kozyra D., Bugiardini E., et al
About 40-50% of patients experience nausea when taking GLP1s, alongside vomiting (15-25%) and constipation (20-30%)